Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment

• Үндсэн зохиолчид: Yingying Zhang (Зохиогч), Hongxia Duan (Зохиогч), Heming Zhao (Зохиогч), Lingling Qi (Зохиогч), Yanhong Liu (Зохиогч), Zheao Zhang (Зохиогч), Chao Liu (Зохиогч), Liqing Chen (Зохиогч), Mingji Jin (Зохиогч), Youyan Guan (Зохиогч), Zhonggao Gao (Зохиогч), Wei Huang (Зохиогч)
• Формат: Ном
• Хэвлэсэн: MDPI AG, 2022-04-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Primary prostate cancer (PC) progresses to castration-resistant PC (CRPC) during androgen deprivation therapy (ADR) in early stages of prostate cancer. Thus, rather than blocking the androgen-related pathway further, docetaxel (DTX)-based therapy has become the most effective and standard first-line...